The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim results of a phase II study of the mTOR inhibitor everolimus in patients with pretreated metastatic gastric and esophageal adenocarcinoma.
Zev A. Wainberg
No relevant relationships to disclose
Ravi Patel
No relevant relationships to disclose
Brian DiCarlo
No relevant relationships to disclose
David J Park
No relevant relationships to disclose
Frederic C. Kass
No relevant relationships to disclose
Andre K. D. Liem
No relevant relationships to disclose
He-jing Wang
No relevant relationships to disclose
Diego Martinez
No relevant relationships to disclose
J. Randolph Hecht
No relevant relationships to disclose